Ketamine infusion vs Spravato vs compounded nasal or oral ketamine: four different records
FDA-approved ketamine injection is an anesthetic; psychiatric ketamine infusions are off-label. Spravato is FDA-approved esketamine nasal spray with indication-specific labeling and a REMS. Compounded ketamine nasal or oral products are not FDA-approved and do not inherit Spravato's evidence or authorization.
Ketamine infusion, Spravato, and compounded ketamine nasal or oral products are not interchangeable routes to the same FDA approval. FDA-approved ketamine injection is labeled as an anesthetic; using ketamine infusion for a psychiatric condition is off-label. Spravato contains esketamine and has product-specific psychiatric indications, supervised dosing, at least two hours of monitoring, and a REMS. Compounded ketamine products are not FDA-approved and do not inherit Spravato’s label, device, dose, evidence, or REMS status.123
“FDA-approved ketamine clinic” is therefore an incomplete claim. The molecule, finished product, route, indication, setting, prescriber, monitoring, and source must align.
Four pathways, four different records
| Offering | Regulatory starting point | Verification focus |
|---|---|---|
| Ketamine injection for anesthesia | FDA-approved ketamine drug used within its anesthetic labeling | Exact product, indication, IV or IM route, anesthesia personnel, monitoring, facility, and label |
| Ketamine infusion for a psychiatric condition | Off-label use of an approved ketamine injection | Diagnosis, prescriber rationale, infusion protocol, evidence, monitoring, emergency capacity, coordination, and follow-up |
| Spravato nasal spray | FDA-approved esketamine product for its labeled adult psychiatric indications under a REMS | Patient eligibility, certified setting, supervised administration, dose, observation, transport, and longitudinal care |
| Compounded nasal, oral, sublingual, or lozenge ketamine | Section 503A or 503B pathway when all applicable conditions are met; finished product is not FDA-approved | Compounder category, formulation, route, dose expression, quality, ordering or prescription basis, home-versus-clinic use, monitoring, and compounding record |
| Internet ketamine product | May be unapproved, misbranded, counterfeit, unlawfully distributed, or not what it claims | Do not infer legitimacy from an NDC, prescription form, telehealth page, or professional-looking package |
The 2026 Ketalar label identifies ketamine hydrochloride injection as an IV or IM general anesthetic for specified diagnostic and surgical contexts.1 That approval supports the finished product and labeled use, not psychiatric infusion as an approved indication.
Off-label does not mean unreviewed care can be vague
Licensed prescribers may use an approved drug off-label in clinical practice, but the clinic should be precise about the departure from labeling. For a psychiatric ketamine infusion, ask:
- diagnosis, treatment history, and clinician responsible for longitudinal mental-health care;
- exact ketamine injection product, manufacturer, concentration, lot, and source;
- route, calculated dose, infusion duration, number and spacing of sessions;
- evidence for the population, protocol, comparator, endpoint, and follow-up;
- blood pressure, oxygenation, mental-status, airway, and recovery monitoring;
- screening for medicines, substance-use context, cardiovascular or other contraindication questions;
- acute distress, prolonged symptoms, mania, psychosis, suicidality, misuse, and emergency pathways; and
- maintenance, nonresponse, discontinuation, and transition plan.
This is not a recommendation to receive or avoid treatment. It is the minimum information needed to distinguish a controlled off-label clinical plan from a branded experience.
Spravato is esketamine plus a restricted delivery system
Spravato contains esketamine, one component of racemic ketamine. Its current label includes specific adult indications and a boxed warning addressing sedation, dissociation, respiratory depression, abuse and misuse, and suicidal thoughts and behaviors in relevant populations.2 The product is administered under direct observation in a certified health-care setting, followed by monitoring for at least two hours; patients do not take it home.
The REMS certifies settings and pharmacies and establishes dispensing and monitoring controls.5 “We use the same molecule family” does not let a compounded spray borrow that REMS or the Spravato trials. Likewise, being a Spravato-certified clinic does not make every separate ketamine service FDA approved.
Ask whether the appointment is billed and documented as Spravato, ketamine infusion, or another product. The consent, drug record, route, dose, claim, and monitoring should match the answer.
Compounded ketamine adds formulation and home-use questions
FDA states that compounded drugs are not FDA-approved and has issued safety alerts about compounded ketamine, including nasal and oral formulations, for psychiatric uses.3 A section 503A pharmacy and a section 503B outsourcing facility follow different conditions; FDA explains that a 503B facility may or may not receive patient-specific prescriptions.6 Neither pathway creates a generic version of Spravato or an approved home protocol.
Verify:
- dispensing pharmacy and state license;
- any claimed 503B outsourcing facility as a separate record;
- patient-specific prescription and clinical-difference basis where applicable, or documented 503B order and compounding basis;
- racemic ketamine versus esketamine, salt form, concentration, total amount, and dose expression;
- nasal device, lozenge, capsule, or liquid instructions;
- lot, beyond-use date, storage, shipping temperature, and package integrity;
- who observes administration and what physiologic and mental-status monitoring occurs; and
- diversion, misuse, leftover-drug, emergency, and discontinuation plans.
The compounding verification guide keeps pharmacy license, FDA registration, inspection, and drug approval distinct.
A warning letter is not a category approval or ban
FDA’s June 2026 Med Shop warning letter is a product- and conduct-specific enforcement record. It states that the offered ketamine nasal spray lacked an approved application, distinguishes approved ketamine anesthesia from Spravato, and summarizes the latter’s REMS constraints.4 It does not mean every ketamine service has the same facts.
Read a warning letter with its date, recipient, products, claims, law cited, and later status. The FDA action-types guide explains why a warning letter is not a recall, approval decision, or transferable verdict.
Telehealth separates platform, prescriber, pharmacy, and setting
An online intake may connect a patient to a prescriber and dispensing pharmacy, but the website itself does not authenticate either. Match the clinician to a license valid for the patient’s location, the controlled-substance authority relevant to the prescription, the pharmacy, the finished product, and the follow-up plan. The new NPI-versus-license guide explains why an identifier is not authority.
If doses are taken at home, ask what replaces continuous onsite observation: responsible adult, transportation, blood-pressure or other measurements, real-time contact, emergency criteria, storage, child or household protection, and next-day follow-up. Do not let “low dose” substitute for those controls.
Compare programs on one ledger
Write down five fields before comparing clinics: molecule, finished product, route, indication, and oversight pathway. Spravato, IV ketamine, and a compounded nasal product will separate naturally once every field is matched to its own label and record.
Sources
- U.S. Food and Drug Administration. KETALAR Prescribing Information. Current 2026 ketamine injection label establishing approved anesthetic indications, IV or IM route, dosing context, monitoring, and warnings. Accessed .
- U.S. Food and Drug Administration. SPRAVATO Prescribing Information. Current esketamine nasal-spray indications, boxed warning, supervised administration, two-hour monitoring, dosing, and REMS requirements. Accessed .
- U.S. Food and Drug Administration. Compounding Risk Alerts. FDA's current collection of safety alerts for compounded ketamine nasal and oral products used for psychiatric disorders. Accessed .
- U.S. Food and Drug Administration. Med Shop Inc. Warning Letter. June 2026 product-specific enforcement example distinguishing unapproved ketamine nasal spray, approved anesthetic ketamine, and approved REMS-constrained Spravato. Accessed .
- U.S. Food and Drug Administration. SPRAVATO REMS. Current REMS document for certified settings and pharmacies, supervised administration, and post-dose monitoring. Accessed .
- U.S. Food and Drug Administration. Questions and Answers: Outsourcing Facility Registration. Official distinction explaining that a section 503B outsourcing facility may or may not obtain patient-specific prescriptions and remains subject to pathway-specific conditions. Accessed .